Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: V09IX12

Axumin(fluciclovine (18F))

Prostatic Neoplasms;Radionuclide Imaging

Marketing Authorisation Holder: Blue Earth Diagnostics Ireland Ltd

EMA Authorisation: 21/05/2017

INN: fluciclovine (18F)

Indication

This medicinal product is for diagnostic use only. Axumin is indicated for Positron Emission Tomography (PET) imaging to detect recurrence of prostate cancer in adult men with a suspected recurrence based on elevated blood prostate specific antigen (PSA) levels after primary curative treatment.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Axumin — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.